Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Role of IL5 in Epithelial Cell Integrity
NCT05895929Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1 trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Change in Type 1 inflammatory markers at 48 hours, Change in Type 2 inflammatory markers at 48 hours and 3 more. Started Sep 2023; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05895929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895929.